Replies to post #131045 on Biotech Values

[ghmm]

VRTX:

I realize the book was talking mainly about the development of a transplant drug on some HCV work (that Boger didn't want to get into). What the book spoke to me most about was their culture which in retrospect hearing company presentations seemed still present.

There are two major things that stick out.
1) I basically have the sense they think they are better then everyone (probably common and not necessarily bad in a modest degree but I sense a much higher level with VRTX).
2) Shareholders are seen only as a source for funds. Maybe that is why Emmens was bought in?

I agree with all you wrote on VRTX I am a bit skeptical on how big the CF drugs can be and I think if Management would swallow some pride they could probably get more life out of Incivek.

[DewDiligence]

VRTX—I guess the burning question is how much cash they rake in on their HCV drug before the all-orals get on the market and how much they spend on dumb stuff in the meantime.

An ancillary question is the degree to which VRTX itself will benefit from the move to all-oral HCV cocktails. They do, after all, have VX-222 and the two nukes they in-licensed from Alios (#msg-64166913).